Johnson & Johnson Says FDA OKs ICOTYDE, First Oral IL-23 Receptor Antagonist For Plaque Psoriasis

FDA approved ICOTYDE (icotrokinra), an IL-23 receptor antagonist, for treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients age 12+. Johnson & Johnson announced the approval, enabling a new commercial launch that expands its dermatology portfolio. The approval is supportive for J&J's fundamentals and could drive a modest stock move (roughly 1–3%) and incremental revenue upside, though no sales guidance was provided in the release.

Analysis

FDA approved ICOTYDE (icotrokinra), an IL-23 receptor antagonist, for treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients age 12+. Johnson & Johnson announced the approval, enabling a new commercial launch that expands its dermatology portfolio. The approval is supportive for J&J's fundamentals and could drive a modest stock move (roughly 1–3%) and incremental revenue upside, though no sales guidance was provided in the release.